MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Cardiology, Cardiovascular
Cardiovascular: Key Therapies
Heart Valves
Parents
Cardiovascular: Key Therapies
Children
*Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive
*Architects: Cardiovascular, Cardiac & Cardiology Companies _ Heart Valves, Ventricular Assist (LVAD,pVAD), Artificial Heart
*Architects: Surgical Technology _ Cardiovascular, Cardiac & Cardiology Companies
*Catheter-based technology that offers a less invasive alternative to traditional open heart surgery while ensuring precise and reliable placement of the heart valve implant
*DEVELOPS PRODUCTS TO TREAT ADVANCED CARDIOVASCULAR DISORDERSINCLUDING HEART VALVE AND PERIPHERAL VASCULAR DISEASE.
*Founded to develop a transcatheter heart valve system to treat patients who suffer from aortic stenosis
*Funding: NIH_NHLBI
*Heart valve maker
*Interventional tools for treatment of heart failure and mitral valve regurgitation.
*Pioneers: Pediatrics
*Products include Anteris' DurAVR transcatheter heart valve for younger patients, ComASUR, a delivery system that allows accurate valve placement, and tADAPT regenerative tissue products.
*Valgen focus on treatment technologies and systemic solutions for heart disease, especially for mitral and tricuspid valve lesions.
2010: Boston Scientific Acquires Sadra for $193M Upfront, Gets Device To Fix Heart Valves
2011: Marvels of Medical Technology: Sapien Transcatheter heart valve (2011)
2011: No. 1 maker of heart valves (2011)
2016: Edwards Lifesciences Soars To New High As Heart Valve Aces Trial
2017: VA_65--506-18-1-984-0350/ TAVR HEART VALVE_Medtronic
2018: Edwards Lifesciences (EW)_ Can This IBD 50 Stock Stem Its Share Losses In Heart-Valve Replacements?www.investors.com
2018: VA_Edwards LifeScience_65--(TAVR) Transcatheter Heart Valve Replacement
2021: Hybrid Tissue Engineered-Regen Med Heart Valve Can Grow in Recipient
2021: NASEM Panel_DRUG RESEARCH AND DEVELOPMENT FOR ADULTS ACROSS THE OLDER AGE SPAN
2022: Edwards’ Sapien 3 transcatheter pulmonary valve system with Alterra adaptive present is a catheter-based stent and artificial heart valve for treating patients whose right ventricular outflow tract becomes too leaky.
2022: Google unveils smartphone-based AI for diabetic retinopathy, heart valve disorders
2024: Capstan Medical collects $110M for robotic heart valve replacements
2024: Edwards Lifesciences: Sapien 3 Ultra Resilia Transcatheter Aortic Heart Valve (also nominated in 2024)
2024: Heart valve developer Anteris launches IPO
2025: 12 things to know about the transcatheter heart valves market
2025: What's next after Capstan's first-in-human robotic heart valve cases
2026: AI Stethoscope Doubles Detection of Valvular Heart Disease
2026: NHLBI_NOSI: Administrative Supplements to Encourage Research in Valvular Heart Disease (CAROL Act)
2026: NHLBI_NOSI: Research Project Grants in Valvular Heart Disease (CAROL Act)
2026: Transcatheter heart valves market to enjoy solid growth ...The transcatheter heart valves market will grow at an 8.4% CAGR over the rest of the decade
A device company developing revolutionary percutaneous heart valve (PHV) products, such as a more durable artificial aortic valve with the beneficial properties of a natural tissue valve, and a catheter delivery system which can be used with any percutaneo
Anteris Technologies Global Corporation
AorTx is developing device solutions that rapidly convert aortic valve replacement from being one of the most severely invasive heart surgical procedures to that of a minimally invasive, percutaneous, approach.
Apparatus for Successful Tissue Engineered Heart Valve-Children's Hospital Boston
Application of Automation and Tissue Engineering to Construct Heart Valves
Architects: Cardiovascular, Cardiac & Cardiology Companies
Architects: Cardiovascular, Cardiac & Cardiology Companies _ Congestive Heart Failure (CHF)
Atrial Fibrillation
Biocompatible polymer implant to prevent or reverse the progression of chronic heart failure and mitral valve regurgitation
Cardiology, Cardiovascular
CardioPolymers is developing novel biocompatible polymer implant therapies to treat chronic heart failure, mitral valve regurgitation and post-operative atrial fibrillation.
Cardiosolutions is developing a catheter-based approach to repair mitral valves without open-heart surgery
Catheter Technology
Chamber, Circuit and Method for evaluating Tissue Engineered Heart Valves-Children's Hospital Boston
Company's devices consist of a range of non-implantable, catheter-based therapies to create new vein valves for patients who are unable to efficiently pump blood out of their legs and back to their hearts.
Developer of an aortic heart valve.
Developmental-stage medical device company focused on percutaneous mitral heart valve replacement
Devices to treat heart valve disorders
Edwards Lifesciences Corporation (NYSE: EW)
Fibre-Reinforced Material for Prosthetic Heart Valves-Children's Hospital Boston
Florida International University-Catheter deliverable artificial multi-leaflet heart valve prosthesis and intravascular delivery system Cardiac BioSolutions—
Foldax is working on a next-gen heart valve alongside new manufacturing processes that tap robotic technology to make production more efficient and pandemic-proof.
Guidewires
Heart Valve
Heart Valve Repair
Heart Valve Replacement
Heart valve replacement and repair products
Heart Valve Therapies
Heart Valves = $832 million (2001)
However, only a Small Percentage of Those Are Treated with the Current Standard of Care, Valve Replacement during Open-heart Surgery Using Cardiopulmonary Bypass.
Lepu has built up a leading group company concentrating in cardiac therapy, with products including interventional cardiology, occlusion devices, prosthetic heart valves, pacemaker, cardiac in vitro diagnosis products, angiographic equipment and anesthetic
Medtronic plc (Ireland) (NYSE:MDT)
Neovasc manufactures biological tissue for incorporation into devices such as transcatheter heart valves and to treat vascular disease
New heart valve design has demonstrated excellent function in animal studies
Next generation heart valve approach
Novel Design for Replacement Heart Valve Leaflets-Children's Hospital Boston
Novel Two Piece Replacement Heart Valve Delivered via Transcatheter-Children's Hospital Boston
On-X® LTI designed and manufactures the On-X® Prosthetic Heart Valve, the most advanced prosthetic heart valve available
Philips HeartNavigator System for Transcatheter Heart Valve Implantation Receives FDA Clearance (2011)
Recent years have seen Cleveland Clinic breakthroughs in heart valve repair, minimally invasive cardiac surgery and the genetics
Symetis is a Swiss Company developing innovative minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases.
The WCS blood pump, TORVADTM, eliminates inlet and outlet valves while providing capability for control and synchronization with the native heart over a wide range of blood flows from near steady flow to pulsatile flow.
Treatment of congestive heart failure and mitral valve insufficiency.
Tria™ heart valves are made with revolutionary new LifePolymer™ material and designed to last a lifetime
TTVR (Transcatheter Tricuspid Valve Replacement)
Two-part heart valve including an exchangeable bioprosthetic tissue.
University of Minnesota invented the pacemaker, the heart valve and one of the Web's first Internet browsers
Ventritex (acquired by St. Jude Medical) manufactures mechanical and tissue heart valves, pacemakers, implantable cardioverter d